2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-133036
    APJ receptor agonist 1 2287153-38-0 98%
    APJ receptor agonist 1, a biphenyl acid derivative, is a potent APJ receptor (APJ-R) agonist (EC50s 0.093 and 0.12 nM for human and rat APJ-R, respectively). APJ receptor agonist 1 displays in vitro potency to apelin-13, the endogenous peptidic ligand for the APJ receptor. APJ receptor agonist 1 has the potential for the research of heart failure.
    APJ receptor agonist 1
  • HY-133214
    Cyclazosin hydrochloride 146929-33-1 98%
    Cyclazosin hydrochloride is an α1B-adrenergic receptor antagonist. Cyclazosin hydrochloride has high specificity for α-adrenergic receptors, with pKi values of 9.23-9.57 and 8.18-8.41 for O/1A (O/la) and OflB (alb) adrenergic receptors, respectively. However, Cyclazosin hydrochloride cannot distinguish between cloned alb and alo adrenergic receptors, which have pKi values of 9.23 and 9.28, respectively.
    Cyclazosin hydrochloride
  • HY-13338A
    (S)-Mabuterol 56707-25-6 98%
    (S)-Mabuterol is a selective β2 adrenoreceptor agonist that demonstrates blood pressure reduction and increased heart rate and contractile force in animal models.
    (S)-Mabuterol
  • HY-13338S
    Mabuterol-d9 1246819-58-8 98%
    Mabuterol-d9 is a deuterium labeled Mabuterol. Mabuterol is an agonist of the β2-adrenergic receptor.
    Mabuterol-d9
  • HY-133567
    SET7-IN-DC21 2567886-53-5 98%
    SET7-IN-DC21 is a selective, potent SET7 inhibitor (IC50 = 15.93 μM; KD = 18.00 μM). SET7-IN-DC21 has good selectivity for several other epigenetic targets, such as SUV39H1, G9a, NSD1, DOT1L and MOF. SET7-IN-DC21 can be used for the researches of cancer, infection, inflammation, metabolic and cardiovascular disease, such as breast cancer.
    SET7-IN-DC21
  • HY-133589
    Fulvine 6029-87-4 98%
    Fulvine is a pyrrolizidine alkaloid isolated from the seeds of Crotalaria fulva. Fulvine is hepatotoxic and can be used to induce hypertensive pulmonary vascular disease in vivo.
    Fulvine
  • HY-133715
    Pilsicainide 88069-67-4 98%
    Pilsicainide (SUN 1165 free acid) is a potent sodium channel blocker and potent class Ic antiarrhythmic agent.
    Pilsicainide
  • HY-133890
    Tauro-α-muricholic acid 25613-05-2 99.18%
    Tauro-alpha-muricholic acid (T-alpha-MCA) is a bile acid that belongs to a class of compounds that are synthesized in the liver and play an important role in the digestive process. Tauro-α-muricholic acid activates Farni X receptors (FXR) which are involved in the regulation of bile acid synthesis, metabolism and transport. Tauro-alpha-muricholic acid can be used in the study of metabolic syndrome and cardiovascular disease.
    Tauro-α-muricholic acid
  • HY-133924
    18-Deoxyherboxidiene 1200128-66-0 98%
    18-Deoxyherboxidiene (RQN-18690A) is a potent angiogenesis inhibitor. 18-Deoxyherboxidiene targets SF3b, a spliceosome component that is a subcomplex of the U2 small nuclear ribonucleoprotein (snRNP) in the spliceosome. 18-Deoxyherboxidiene inhibits the migration and tube formation of human umbilical vein endothelial cells (HUVECs) without significant cell toxicity. 18-Deoxyherboxidiene has the potential for cancer research.
    18-Deoxyherboxidiene
  • HY-134101
    2-O-Ethyl PAF C-16 78858-42-1 98%
    2-O-Ethyl PAF C-16 is a homolog of PAF and a competitive ligand for PAF receptor (Platelet-activating Factor Receptor (PAFR)). 2-O-Ethyl PAF C-16 inhibits the binding of the PAF antagonist WEB 2086 (HY-108634) to the PAF receptor with an IC50 of 21 nM.
    2-O-Ethyl PAF C-16
  • HY-134221
    S-Nitroso-N-acetylcysteine 56577-02-7 98%
    S-Nitroso-N-acetylcysteine is a nitric oxide donor. S-Nitroso-N-acetylcysteine has a tissue vascular dilation effect, which can enhance liver microcirculation and effectively prevent ischemia-reperfusion injury in fatty liver. S-Nitroso-N-acetylcysteine can reduce liver fibrosis in rats with cirrhosis.
    S-Nitroso-N-acetylcysteine
  • HY-134263
    8-Br-cAMP-AM 190522-24-8 98%
    8-Br-cAMP-AM is a cyclic adenosine monophosphate (cAMP) analog that activates two major signal transduction pathways in the heart by mimicking the effects of cAMP: protein kinase A (PKA) and guanosine nucleotide exchange factor (Epac), which is directly activated by cAMP. 8-Br-cAMP-AM can be used to study cardiac ischemia and reperfusion injury.
    8-Br-cAMP-AM
  • HY-134264
    8-Br-2'-O-Me-cAMP 612513-13-0 98%
    8-Br-2'-O-Me-cAMP is an analogue of the signal molecule cyclic AMP (cAMP). 8-Br-2'-O-Me-cAMP is an agonist of exchange factors activated by cAMP (Epac), while it doesn't activate PKA as cAMP do. 8-Br-2'-O-Me-cAMP can be used in cardiovascular disease research.
    8-Br-2'-O-Me-cAMP
  • HY-13441G
    (-)-Blebbistatin (GMP) 856925-71-8 98%
    (-)-Blebbistatin (GMP) is (-)-Blebbistatin (HY-13441) produced by using GMP guidelines. (-)-Blebbistatin (GMP) is a selective inhibitor of the ATPase activity of non-muscle myosin II.
    (-)-Blebbistatin (GMP)
  • HY-13443S
    Exendin-4 (Leu-13C6,15N) TFA 98%
    Exendin-4 (Leu-13C6,15N) (Exenatide (Leu-13C6,15N)) TFA is the 13C- and 15N-labeled Exendin-4 TFA (HY-13443). Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.
    Exendin-4 (Leu-13C6,15N) TFA
  • HY-134482
    PCSK9-IN-1 2730022-10-1 98%
    PCSK9-IN-1 is a novel and highly potent cyclic peptide PCSK9 inhibitor with a Ki value of 1.46 nM.
    PCSK9-IN-1
  • HY-13458A
    Droxidopa hydrochloride 1260173-94-1 98%
    Droxidopa (L-DOPS) hydrochloride is a potent, orally active norepinephrine precursor. Droxidopa hydrochloride increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa hydrochloride has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder).
    Droxidopa hydrochloride
  • HY-13467A
    (R)-AM-1638 1142222-18-1
    (R)-AM-1638 is an orally active full agonist of GPR40 (EC50: 0.16 μM). (R)-AM-1638 increases the expression of antioxidant molecules (HO-1 and NQO-1). AM1638 blocked Palmitate (HY-N0830)-mediated superoxide production and ER stress. (R)-AM-1638 has antidiabetic activity and improves glycemic control in BDF mice with diet-induced obesity (DIO). (R)-AM-1638 demonstrates excellent oral bioavailability (mouse, >100%; rat, 72%; and cyno, 71%).
    (R)-AM-1638
  • HY-134913
    Rhodblock 1a 701226-08-6 98%
    Rhodblock 1a is an inhibitor of the Rho kinase signaling pathway. It inhibits the normal formation of the cleavage furrow during cell division by interfering with the localization and function of Rho pathway proteins, causing some cells to fail to form a cleavage furrow or the formed cleavage furrow to break, resulting in binucleated cells. Rhodblock 1a can be used to study the mechanism of cell division and is expected to be used in the research of diseases such as cardiovascular diseases and cancer.
    Rhodblock 1a
  • HY-135151
    Difluoro atorvastatin 693794-20-6 98%
    Difluoro atorvastatin (Fluoroatorvastatin) is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
    Difluoro atorvastatin
Cat. No. Product Name / Synonyms Application Reactivity